Targeting p300 Addiction in <i>CBP</i> -Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of <i>MYC</i> Expression

Abstract

Targeting synthetic-lethal partners of genes mutated in cancer holds great promise for treating patients without activating driver gene alterations. Here, we propose a "synthetic lethal-based therapeutic strategy" for CBP-deficient cancers by inhibition of the p300 HAT activity. Patients with CBP-deficient cancers could benefit from therapy using p300-HAT inhibitors.